EPCAM and neoplasm: These antibody-based therapeutics deliver drugs or cytokines directly to the tumor via EpCAM-targeting antibodies, enabling ADCs or immunocytokines to specifically kill tumor cells or activate immune cells within the tumor microenvironment, thereby offering enhanced efficacy and safety.